US Stock MarketDetailed Quotes

MRUS Merus

Watchlist
  • 40.200
  • -0.100-0.25%
Close Feb 14 16:00 ET
  • 40.200
  • 0.0000.00%
Post 16:01 ET
2.75BMarket Cap-9.98P/E (TTM)

About Merus Company

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Company Profile

SymbolMRUS
Company NameMerus
Listing DateMay 19, 2016
Issue Price10.00
Founded2003
CEODr. Sven Ante Lundberg, M.D.
MarketNASDAQ
Employees229
Fiscal Year Ends12-31
AddressUppsalalaan 17,3rd-4th Floor
CityUtrecht
ProvinceUtrecht
CountryNetherlands (the)
Zip Code3584 CM
Phone31-30-253-88-00
Websitehttp://www.merus.nl

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Sven Ante Lundberg, M.D.
  • Director, President and Chief Executive Officer
  • 4.67M
  • Gregory D. Perry
  • Chief Financial Officer
  • 6.21M
  • Peter B. Silverman, J.D.
  • Chief Operating Officer and General Counsel
  • 1.95M
  • Dr. Fabian Zohren, M.D.,PhD
  • Chief Medical Officer
  • --
  • Harry Shuman
  • Chief Accounting Officer
  • --
  • Dr. Anand Mehra, M.D.
  • Chairman of the Board
  • 417.56K
  • Dr. Victor Sandor, C.M.,M.D.
  • Independent Director
  • 303.56K
  • Paolo Pucci
  • Independent Director
  • 309.56K
  • Dr. Maxine Gowen,PhD
  • Independent Director
  • 305.06K
  • Len Kanavy
  • Independent Director
  • 303.56K
  • Mark T. Iwicki
  • Independent Director
  • 311.06K
  • Jason Haddock
  • Independent Director
  • --

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Earnings Season Underway
Earnings season is here. What to know?
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More
TSLA earnings preview: Grab rewards by guessing the opening price!